Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes

Open access

Abstract

We report a group of patients presenting with a progressive dementia syndrome characterized by predominant dysfunction in core executive functions, relatively young age of onset and positive biomarkers for Alzheimer’s pathophysiology. Atypical frontal, dysexecutive/behavioural variants and early-onset variants of Alzheimer’s disease have been previously reported, but no diagnostic criteria exist for a progressive dysexecutive syndrome. In this retrospective review, we report on 55 participants diagnosed with a clinically defined progressive dysexecutive syndrome with 18F-fluorodeoxyglucose-positron emission tomography and Alzheimer’s disease biomarkers available. Sixty-two per cent of participants were female with a mean of 15.2 years of education. The mean age of reported symptom onset was 53.8 years while the mean age at diagnosis was 57.2 years. Participants and informants commonly referred to initial cognitive symptoms as ‘memory problems’ but upon further inquiry described problems with core executive functions of working memory, cognitive flexibility and cognitive inhibitory control. Multi-domain cognitive impairment was evident in neuropsychological testing with executive dysfunction most consistently affected. The frontal and parietal regions which overlap with working memory networks consistently demonstrated hypometabolism on positron emission tomography. Genetic testing for autosomal dominant genes was negative in all eight participants tested and at least one APOE ε4 allele was present in 14/26 participants tested. EEG was abnormal in 14/17 cases with 13 described as diffuse slowing. Furthermore, CSF or neuroimaging biomarkers were consistent with Alzheimer’s disease pathophysiology, although CSF p-tau was normal in 24% of cases. Fifteen of the executive predominate participants enrolled in research neuroimaging protocols and were compared to amnestic (n = 110), visual (n = 18) and language (n = 7) predominate clinical phenotypes of Alzheimer’s disease. This revealed a consistent pattern of hypometabolism in parieto-frontal brain regions supporting executive functions with relative sparing of the medial temporal lobe (versus amnestic phenotype), occipital (versus visual phenotype) and left temporal (versus language phenotype). We propose that this progressive dysexecutive syndrome should be recognized as a distinct clinical phenotype disambiguated from behavioural presentations and not linked specifically to the frontal lobe or a particular anatomic substrate without further study. This clinical presentation can be due to Alzheimer’s disease but is likely not specific for any single aetiology. Diagnostic criteria are proposed to facilitate additional research into this understudied clinical presentation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/braincomms/fcaa068

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical Abstract
Graphical Abstract CC BY · PubMed Central
Figure 1 Box 2 Example Case Neuroimaging at presentation (2 years of symptoms) with (A) FDG–PET (Cortex ID, GE Healthcare) showing severe bilateral right > left temporal, parietal, precuneus, posterior cingulate and frontal hypometabolism; (B) MRI Axial T2 Flair and Coronal T1 images with mild right parietal atrophy with no frontal or hippocampal atrophy; (C) 18F-AV1451 tau PET with severe global tau radiotracer uptake; (D) Positive PiB amyloid-PET.
Figure 1 Box 2 Example Case Neuroimaging at presentation (2 years of symptoms) with (A) FDG–PET (Cortex ID, GE Healthcare) showing severe bilateral right > left temporal, parietal, precuneus, posterior cingulate and frontal hypometabolism; (B) MRI Axial T2 Flair and Coronal T1 images with mild right parietal atrophy with no frontal or hippocampal atrophy; (C) 18F-AV1451 tau PET with severe global tau radiotracer uptake; (D) Positive PiB amyloid-PET.CC BY · PubMed Central
Figure 2 Discordance of CSF p-tau biomarkers and tau PET in five participants who had CSF p-tau in the normal range (< 61 pg/ml). Left: FDG–PET (using Cortex ID, GE Healthcare) with z-score bar at the top. Middle:18F-AV1451 tau PET with SUVR bar at the top and individual meta-ROI SUVR below each image. Right: PiB amyloid PET with SUVR bar at the top and individual meta-ROI SUVR below each image. Significant 18F-AV1451 uptake was present in all five participants (mean SUVR 2.05). CSF p-tau level, tau PET SUVR and mean time lag between CSF and tau PET for each participant can be found in Supplementary Table 1. *Bottom participant came to autopsy and was found to have A3, B3, C3 Alzheimer’s disease pathology.
Figure 2 Discordance of CSF p-tau biomarkers and tau PET in five participants who had CSF p-tau in the normal range (< 61 pg/ml). Left: FDG–PET (using Cortex ID, GE Healthcare) with z-score bar at the top. Middle:18F-AV1451 tau PET with SUVR bar at the top and individual meta-ROI SUVR below each image. Right: PiB amyloid PET with SUVR bar at the top and individual meta-ROI SUVR below each image. Significant 18F-AV1451 uptake was present in all five participants (mean SUVR 2.05). CSF p-tau level, tau PET SUVR and mean time lag between CSF and tau PET for each participant can be found in Supplementary Table 1. *Bottom participant came to autopsy and was found to have A3, B3, C3 Alzheimer’s disease pathology.CC BY · PubMed Central
Figure 3 Molecular neuroimaging and heterogeneity in dysexecutive Alzheimer’s disease of the remaining participants with all three molecular imaging modalities available (participant in Fig. 5 not included). Participants are separated into two columns. Within each column: Left: FDG–PET (using Cortex ID, GE Healthcare) with z-score bar at the top. Middle:18F-AV1451 tau PET with SUVR bar at the top and individual meta-ROI SUVR below each image. Right: PiB amyloid-PET with SUVR bar at the top and individual meta-ROI SUVR below each image. There is hypometabolism and tau PET uptake predominantly in the dorsolateral prefrontal, lateral temporoparietal, precuneus and posterior cingulate regions, with inter-individual heterogeneity in topography and degree of involvement. CSF p-tau level, tau PET SUVR and mean time lag between CSF and tau PET for each participant can be found in Supplementary Table 1.
Figure 3 Molecular neuroimaging and heterogeneity in dysexecutive Alzheimer’s disease of the remaining participants with all three molecular imaging modalities available (participant in Fig. 5 not included). Participants are separated into two columns. Within each column: Left: FDG–PET (using Cortex ID, GE Healthcare) with z-score bar at the top. Middle:18F-AV1451 tau PET with SUVR bar at the top and individual meta-ROI SUVR below each image. Right: PiB amyloid-PET with SUVR bar at the top and individual meta-ROI SUVR below each image. There is hypometabolism and tau PET uptake predominantly in the dorsolateral prefrontal, lateral temporoparietal, precuneus and posterior cingulate regions, with inter-individual heterogeneity in topography and degree of involvement. CSF p-tau level, tau PET SUVR and mean time lag between CSF and tau PET for each participant can be found in Supplementary Table 1.CC BY · PubMed Central
Figure 4 Age of onset association with tau PET burden: Scatter plots of the 20 participants with tau PET scans: (A) A younger age of onset was associated with a higher tau PET SUVR (multiple r2 = 0.41; adjusted r2 = 0.38, P < 0.005). (B) Years of symptoms prior to tau PET was not statistically significant (multiple r2 = 0.09; adjusted r2 = 0.04, P = 0.21). (C) Higher tau PET SUVR was associated with lower bedside cognitive testing (multiple r2 = 0.33; adjusted r2 = 0.29, P < 0.01).
Figure 4 Age of onset association with tau PET burden: Scatter plots of the 20 participants with tau PET scans: (A) A younger age of onset was associated with a higher tau PET SUVR (multiple r2 = 0.41; adjusted r2 = 0.38, P < 0.005). (B) Years of symptoms prior to tau PET was not statistically significant (multiple r2 = 0.09; adjusted r2 = 0.04, P = 0.21). (C) Higher tau PET SUVR was associated with lower bedside cognitive testing (multiple r2 = 0.33; adjusted r2 = 0.29, P < 0.01).CC BY · PubMed Central
Figure 5 Longitudinal case example: A 54-year-old female with 3 years of mild multi-tasking difficulties before presentation had 3 years of longitudinal molecular imaging with (A) FDG–PET (Cortex ID z-score 0 to −7, GE Healthcare) showing mild hypometabolism that progresses over 3 years. (B) 18F-AV1451 tau PET (SUVR scale 0–2.5) radioligand uptake preceding hypometabolism at each time point. (C) Significant PiB amyloid-PET (SUVR scale 0–3) radioligand uptake in an Alzheimer’s disease pattern. (D) Neuropsychological scores showing mild impairment at initial presentation (green bars) despite already significant tau PET uptake in the bilateral temporal, parietal and frontal lobes. Cognitive impairment progressed at two-time points (red and blue bars) consistent with FDG–PET and tau PET progression. Trails B and Stroop Color-Word testing were severely impaired and multiple cognitive domains were impaired after 3 years. Logical memory based tests were also significantly abnormal but orientation questions on MoCA were not altered until the third time point (6/6, 6/6, 4/6 at each visit). DRS-2, Dementia Rating Scale-2; Rey-O; SUVR, standardized uptake value ratio.
Figure 5 Longitudinal case example: A 54-year-old female with 3 years of mild multi-tasking difficulties before presentation had 3 years of longitudinal molecular imaging with (A) FDG–PET (Cortex ID z-score 0 to −7, GE Healthcare) showing mild hypometabolism that progresses over 3 years. (B) 18F-AV1451 tau PET (SUVR scale 0–2.5) radioligand uptake preceding hypometabolism at each time point. (C) Significant PiB amyloid-PET (SUVR scale 0–3) radioligand uptake in an Alzheimer’s disease pattern. (D) Neuropsychological scores showing mild impairment at initial presentation (green bars) despite already significant tau PET uptake in the bilateral temporal, parietal and frontal lobes. Cognitive impairment progressed at two-time points (red and blue bars) consistent with FDG–PET and tau PET progression. Trails B and Stroop Color-Word testing were severely impaired and multiple cognitive domains were impaired after 3 years. Logical memory based tests were also significantly abnormal but orientation questions on MoCA were not altered until the third time point (6/6, 6/6, 4/6 at each visit). DRS-2, Dementia Rating Scale-2; Rey-O; SUVR, standardized uptake value ratio.CC BY · PubMed Central
Figure 6 Autopsy results from two dysexecutive Alzheimer’s disease participants and one typical Alzheimer’s disease participant. (A–E) A 54-year-old female had 7 years of progressive symptoms that started with organizing/planning difficulties which lead to losing her job. She additionally repeated stories and had difficulty with numbers. Her initial MRI 2 years into symptoms showed moderate left parietal, mild right parietal and left frontal atrophy. Within 6 years her cognition rapidly decreased and her MoCA was zero. On autopsy, she had a Thal amyloid phase of 5 and Braak tangle stage of VI. (A) Upon macroscopic inspection, significant global atrophy was observed affecting parietal and frontal lobes to a greater extent compared to the temporal lobe. (B) Tau pathology was greatest in parietal and (C) frontal cortex compared to (D) temporal cortex. (E) TDP-43 immunohistochemistry in the amygdala revealed sparse neuronal cytoplasmic inclusions and neurites. (F–J) A 62-year-old male participant had 7 years of progressive symptoms that started with impairment in multi-tasking and problem-solving. Over time he developed severe aphasia and apraxia on the right side. (F) Macroscopic inspection revealed global atrophy, predominantly involving the frontal lobe. He had a Thal amyloid phase of 5 and Braak tangle stage of V. (G) The amount of tau pathology observed in the parietal and (H) frontal cortices was greater than that observed in (I) temporal cortex. (J) TDP-43 immunohistochemistry in the amygdala revealed subpial neurites, but no neuronal cytoplasmic inclusions were observed. (K–O) An 84-year-old male was first noted to have symptoms of memory loss with a slow, but significant progression to typical Alzheimer’s dementia. (K) Macroscopic inspection revealed global atrophy without focal lobar involvement. (L) Tau pathology was observed in parietal and (M) frontal cortices to a lesser extent than that observed in (N) temporal cortex. (O) TDP-43 immunohistochemistry in the amygdala revealed sparse neuronal cytoplasmic inclusions and neurites. Scale bar represents 50 μm for tau photomicrographs and 25 μm for TDP-43 photomicrographs.
Figure 6 Autopsy results from two dysexecutive Alzheimer’s disease participants and one typical Alzheimer’s disease participant. (A–E) A 54-year-old female had 7 years of progressive symptoms that started with organizing/planning difficulties which lead to losing her job. She additionally repeated stories and had difficulty with numbers. Her initial MRI 2 years into symptoms showed moderate left parietal, mild right parietal and left frontal atrophy. Within 6 years her cognition rapidly decreased and her MoCA was zero. On autopsy, she had a Thal amyloid phase of 5 and Braak tangle stage of VI. (A) Upon macroscopic inspection, significant global atrophy was observed affecting parietal and frontal lobes to a greater extent compared to the temporal lobe. (B) Tau pathology was greatest in parietal and (C) frontal cortex compared to (D) temporal cortex. (E) TDP-43 immunohistochemistry in the amygdala revealed sparse neuronal cytoplasmic inclusions and neurites. (F–J) A 62-year-old male participant had 7 years of progressive symptoms that started with impairment in multi-tasking and problem-solving. Over time he developed severe aphasia and apraxia on the right side. (F) Macroscopic inspection revealed global atrophy, predominantly involving the frontal lobe. He had a Thal amyloid phase of 5 and Braak tangle stage of V. (G) The amount of tau pathology observed in the parietal and (H) frontal cortices was greater than that observed in (I) temporal cortex. (J) TDP-43 immunohistochemistry in the amygdala revealed subpial neurites, but no neuronal cytoplasmic inclusions were observed. (K–O) An 84-year-old male was first noted to have symptoms of memory loss with a slow, but significant progression to typical Alzheimer’s dementia. (K) Macroscopic inspection revealed global atrophy without focal lobar involvement. (L) Tau pathology was observed in parietal and (M) frontal cortices to a lesser extent than that observed in (N) temporal cortex. (O) TDP-43 immunohistochemistry in the amygdala revealed sparse neuronal cytoplasmic inclusions and neurites. Scale bar represents 50 μm for tau photomicrographs and 25 μm for TDP-43 photomicrographs.CC BY · PubMed Central
Figure 7 FDG–PET in executive predominant presentations versus amnestic, visual and language predominant Alzheimer’s disease phenotypes. The FDG–PET scans from participants with dysexecutive predominate presentations (n = 15) were compared to (A) amnestic predominate (n = 110), (B) visual predominant (n = 18), (C) and language predominant (n = 7) presentations of Alzheimer’s disease. In each panel, the blue-black end of the spectrum encodes the t-score for a greater degree of hypometabolism in the dysexecutive phenotype with red-orange encoding the greater degree of either (A) amnestic, (B) visual or (C) language phenotype. The t-value corresponding to voxel-level P-value of FDR corrected 0.05 (A and B) or uncorrected 0.001 (C) is indicated with arrows in the colour-bar.
Figure 7 FDG–PET in executive predominant presentations versus amnestic, visual and language predominant Alzheimer’s disease phenotypes. The FDG–PET scans from participants with dysexecutive predominate presentations (n = 15) were compared to (A) amnestic predominate (n = 110), (B) visual predominant (n = 18), (C) and language predominant (n = 7) presentations of Alzheimer’s disease. In each panel, the blue-black end of the spectrum encodes the t-score for a greater degree of hypometabolism in the dysexecutive phenotype with red-orange encoding the greater degree of either (A) amnestic, (B) visual or (C) language phenotype. The t-value corresponding to voxel-level P-value of FDR corrected 0.05 (A and B) or uncorrected 0.001 (C) is indicated with arrows in the colour-bar.CC BY · PubMed Central
Figure 8 Violin scatter plots comparing variables between executive (n = 15), amnestic (n = 110), visual (n = 18) and language predominant (n = 7) Alzheimer’s disease phenotypes. There was a significant main effect of phenotype for (A) age at evaluation, (B) age at disease onset and (C) hippocampal volume. There was no significant main effect of phenotype for (D) disease duration, (E) short test of mental status (STMS), (F) or cortical thickness in Alzheimer’s disease signature regions. Pairwise P-values are indicated as follows: ns = 1, *0.05, **0.01, ***0.001, ****0.
Figure 8 Violin scatter plots comparing variables between executive (n = 15), amnestic (n = 110), visual (n = 18) and language predominant (n = 7) Alzheimer’s disease phenotypes. There was a significant main effect of phenotype for (A) age at evaluation, (B) age at disease onset and (C) hippocampal volume. There was no significant main effect of phenotype for (D) disease duration, (E) short test of mental status (STMS), (F) or cortical thickness in Alzheimer’s disease signature regions. Pairwise P-values are indicated as follows: ns = 1, *0.05, **0.01, ***0.001, ****0.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 86 references

Research works printed but not linked: 1

  1. Spreen, 1998, General intellectual ability and assessment of premorbid intelligence, A compendium of neuropsychological tests, 43

Cited by

See all 157

Metadata

Authors
Townley, R. A., Graff-Radford, J., Mantyh, W. G., Botha, H., Polsinelli, A. J., Przybelski, S. A., Machulda, M. M., Makhlouf, A. T., Senjem, M. L., Murray, M. E., Reichard, R. R., Savica, R., Boeve, B. F., Drubach, D. A., Josephs, K. A., Knopman, D. S., Lowe, V. J., Jack, C. R., Petersen, R. C., & Jones, D. T.
Affiliations
  • Mayo Clinic (US)
  • Department of Neurology Mayo Clinic, Rochester, MN 55902, USA
  • Mayo Clinic in Florida (US)
Corresponding author
Jones, David T
Venue
Brain Communications
Published
2020-01-01
Volume
2
Issue
1
Pages
fcaa068-fcaa068
ISSN
2632-1297 (ISSN-L)
OpenAlex
W3031694559
Cited by
145
References
86
Citations by year
2026: 19 · 2025: 20 · 2024: 23 · 2023: 19 · 2022: 27 · 2021: 18 · 2020: 19
FWCI
15.14
Type
journal article
Language
en
Open access
Locations
  • Brain Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • AVID Radiopharmaceuticals, Inc
  • NIH
  • National Institutes of Health (P50 AG016574, U01 AG006786, R37 AG11378, R01 AG054449, R01 AG041851, R01 AG011378, R01 AG034676, R01 AG37491, R01 NS097495)
  • Robert Wood Johnson Foundation
  • Elsie and Marvin Dekelboum Family Foundation
  • Liston Family Foundation
  • Gerald and Henrietta Rauenhorst Foundation
  • Foundation Dr. Corinne Schuler
  • Alexander Family Alzheimer’s Disease Research
  • Mayo Clinic, and the Mayo Foundation for Medical Education and Research
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
Keywords
Alzheimer's disease, executive dysfunction, early-onset Alzheimer's disease, clinical phenotype, FDG-PET hypometabolism, APOE ε4, cerebrospinal fluid biomarkers, EEG slowing, working memory, cognitive flexibility, inhibitory control, differential diagnosis of dementia, clinical criteria

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. https://app.cochat.ai/papers/10.1093/braincomms/fcaa068
The paper
Townley, R. A., Graff-Radford, J., Mantyh, W. G., Botha, H., Polsinelli, A. J., Przybelski, S. A., Machulda, M. M., Makhlouf, A. T., Senjem, M. L., Murray, M. E., Reichard, R. R., Savica, R., Boeve, B. F., Drubach, D. A., Josephs, K. A., Knopman, D. S., Lowe, V. J., Jack, C. R., Petersen, R. C., & Jones, D. T. (2020). Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. Brain Communications. https://doi.org/10.1093/braincomms/fcaa068

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.